Synlogic (NASDAQ:SYBX) Trading Up 6.2%

Share on StockTwits

Synlogic Inc (NASDAQ:SYBX) was up 6.2% on Tuesday . The company traded as high as $2.89 and last traded at $2.73, approximately 433,800 shares changed hands during mid-day trading. A decline of 16% from the average daily volume of 515,925 shares. The stock had previously closed at $2.57.

A number of equities research analysts have recently weighed in on SYBX shares. ValuEngine raised Synlogic from a “hold” rating to a “buy” rating in a research note on Friday, January 3rd. HC Wainwright reissued a “buy” rating and issued a $13.00 target price on shares of Synlogic in a research note on Monday. Piper Jaffray Companies reissued an “overweight” rating and issued a $7.00 target price (down previously from $10.00) on shares of Synlogic in a research note on Wednesday, November 13th. Zacks Investment Research raised Synlogic from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research note on Thursday, January 9th. Finally, Chardan Capital reissued a “buy” rating on shares of Synlogic in a research note on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $13.72.

The company has a debt-to-equity ratio of 0.14, a quick ratio of 12.70 and a current ratio of 12.70. The business has a 50 day moving average price of $2.41 and a two-hundred day moving average price of $3.59. The company has a market cap of $86.86 million, a P/E ratio of -1.34 and a beta of 2.61.

Synlogic (NASDAQ:SYBX) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.09. Synlogic had a negative return on equity of 34.49% and a negative net margin of 4,574.82%. The company had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.46 million. As a group, research analysts expect that Synlogic Inc will post -1.8 EPS for the current year.

A number of large investors have recently made changes to their positions in SYBX. Charles Schwab Investment Management Inc. increased its holdings in Synlogic by 11.1% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 37,208 shares of the biotechnology company’s stock valued at $339,000 after purchasing an additional 3,708 shares during the period. Northern Trust Corp increased its holdings in Synlogic by 17.1% during the 2nd quarter. Northern Trust Corp now owns 201,613 shares of the biotechnology company’s stock valued at $1,835,000 after purchasing an additional 29,401 shares during the period. Parametric Portfolio Associates LLC purchased a new position in Synlogic during the 2nd quarter valued at about $195,000. BlackRock Inc. increased its holdings in Synlogic by 9.4% during the 2nd quarter. BlackRock Inc. now owns 1,317,063 shares of the biotechnology company’s stock valued at $11,986,000 after purchasing an additional 113,665 shares during the period. Finally, Vanguard Group Inc. increased its holdings in Synlogic by 0.3% during the 2nd quarter. Vanguard Group Inc. now owns 770,641 shares of the biotechnology company’s stock valued at $7,013,000 after purchasing an additional 2,558 shares during the period. Institutional investors own 61.00% of the company’s stock.

Synlogic Company Profile (NASDAQ:SYBX)

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Read More: How does a dividend reinvestment plan work?

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.